2023 WHO Expert Committee on the Selection and Use of Essential Medicines – EMLc review attachment: Mebendazole (2026)

Other · WHO Expert Committee on the Selection and Use of Essential Medicines (Secretariat review) · November 19, 2026

WHO Expert Committee on the Selection, 2026-11-19: The WHO review paper behind the 2023 decision to add a 100 mg chewable mebendazole tablet to the children's essential medicines list, recording the 40-50 mg/kg/day divided-dose regimen used for echinococcosis and cysticercosis over at least three months. It documents both the listing change and the high-dose use of the same drug.

Considering that the dose of mebendazole the treatment of echinococcosis and cysticercosis is 40-50 mg/kg daily given in three divided doses (for a minimum duration of 3 months), the availability of a lower strength tablet would allow for a higher dose flexibility.

p. 34

WHO Expert Committee on the Selection, 2026-11-19: The WHO review paper behind the 2023 decision to add a 100 mg chewable mebendazole tablet to the children's essential medicines list, recording the 40-50 mg/kg/day divided-dose regimen used for echinococcosis and cysticercosis over at least three months. It documents both the listing change and the high-dose use of the same drug. WHO committee review document (not a study). The dose statement is a description of published therapeutic practice, recorded here as the WHO document states it, not as a recommendation. Adverse note in the same paper: oral suspensions were not recommended for the EMLc because 'these formulations have stability issues, as the API precipitates over time, with the risk of underdosing'. URL and file opened; 108-page PDF. Prepared for the 2023 WHO Expert Committee cycle. access date, page undated.